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Abstract: Receptor for advanced glycation end-products (RAGE) is known to be involved in both micro- and macro-
vascular complications in diabetes. Among numerous truncated forms of RAGE recently described, the C-terminally 
truncated form of RAGE has received much attention. This form of RAGE, carrying all of the extracellular domains but 
devoid of the transmembrane and intracytoplasmic domains, is released outside from cells, binds ligands including AGEs, 
and is capable of neutralizing RAGE signaling on endothelial cells in culture. This form of RAGE is generated as a splice 
variant and is named endogenous secretory RAGE (esRAGE). Adenoviral overexpression of esRAGE reverses diabetic 
impairment of vascular dysfunction, suggesting that esRAGE may be an important inhibitor of RAGE signaling in vivo 
and potentially be useful for prevention of diabetic vascular complications. An ELISA system to measure plasma esRAGE 
was recently developed, and the pathophysiological roles of esRAGE have begun to be unveiled clinically. Plasma 
esRAGE levels are decreased in patients with several metabolic diseases including type 1 and type 2 diabetes, metabolic 
syndrome and hypertension. In cross-sectional analysis, plasma esRAGE levels are inversely correlated with carotid or 
femoral atherosclerosis. In an observational cohort of patients with end-stage renal disease, cumulative incidence of 
cardiovascular death was signiﬁ  cantly higher in subjects with lower plasma esRAGE levels. These ﬁ  ndings suggest that 
plasma esRAGE may act as a protective factor against and a novel biomarker for the occurrence of metabolic syndrome 
and cardiovascular diseases.
Keywords: receptor for advanced glycation end-products (RAGE), soluble RAGE (sRAGE), endogenous secretory RAGE 
(esRAGE), AGEs, atherosclerosis, metabolic syndrome, inﬂ  ammation
Receptor for Advanced Glycation End-products (RAGE) and its 
C-terminally Truncated Form (endogenous secretory RAGE, esRAGE)
RAGE is a multiligand cell-surface protein that was isolated from bovine lung in 1992 by the group of 
Schmidt and Stern.
1 RAGE belongs to the immunoglobulin superfamily of cell-surface molecules, and 
binds to various ligands including AGEs, S100 (calgranulin), HMGB1 (amphoterin), and amyloid beta-
peptides.
2–4 Ligand engagement of RAGE in endothelial cells activates the transcription factor nuclear 
factor-κB (NF-κB), subsequently leading to increased expression of inﬂ  ammatory mediators such as 
monocyte chemoattractant protein-1 (MCP-1) and vascular cell adhesion molecule-1 (VCAM-1).
5,6 
Accumulated evidence suggests that the receptor for advanced glycation end-products (RAGE) is 
involved in both diabetic micro-
7–12 and macrovascular complications.
13,14
Numerous truncated forms of RAGE have recently been described
15–19 (Fig. 1). Two major spliced 
variants of RAGE mRNA, N-terminal and C-terminal truncated forms, have been most extensively char-
acterized.
16 The N-truncated isoform of RAGE mRNA codes for a 303-amino-acid protein lacking the 
N-terminal signal sequence and the ﬁ  rst V-like extracellular domain. The N-truncated form is incapable 
of binding with AGEs, since the V-domain is critical for binding of the ligand.
1 The N-truncated form of 
RAGE appears to be expressed on the cell surface similar to the full-length RAGE, although its biological 
roles remain to be elucidated
4. It has been suggested that this form of RAGE could be involved in angio-
genic regulation in a fashion independent of the classical RAGE signaling pathway.
4
The C-terminal truncated form of RAGE lacks the exon 10 sequences encoding the transmembrane 
and intracytoplasmic domains.
16 This spliced variant mRNA of RAGE encodes a protein consisting of 347 
amino acids with a 22-amino-acid signal sequence, and is released from cells. This C-truncated form is 




esRAGE was found to be capable of neutralizing 
the effects of AGEs on endothelial cells in culture.
16 
Adenoviral overexpression of esRAGE in vivo in 
mice reverses diabetic impairment of vascular dys-
function.
20 Thus, the decoy function of esRAGE 
may exhibit a feedback mechanism by which 
esRAGE prevents the activation of RAGE signaling. 
It has also been suggested that some soluble RAGE 
(sRAGE) isoforms that could act as decoy receptors 
may be cleaved proteolytically from the native 
RAGE expressed on the cell surface,
21 suggesting 
heterogeneity of the origin and nature of sRAGE. 
This proteolytic generation of sRAGE was initially 
described as occurring in mice.
22 The molecular 
heterogeneity of the diverse types of sRAGE in 
human plasma could exert signiﬁ  cant protective 
effects against RAGE-mediated toxicity.
sRAGE and esRAGE as Potential 
Biomarkers for Cardiovascular and 
Metabolic Diseases: Cross-
sectional Clinical Studies (Table)
Since sRAGE and esRAGE may be involved in 
feedback regulation of the toxic effects of RAGE-
mediated signaling, recent clinical studies have 
focused on the potential signiﬁ  cance of circulating 
sRAGE and esRAGE in a variety of pathophysi-
ological conditions. First, Falcone et al.
23 reported 
that total sRAGE levels are signiﬁ  cantly lower in 
patients with angiographically proven coronary 
artery disease (CAD) than in age-matched healthy 
controls. The association between circulating 
sRAGE and angiographic observations was shown 
to be dose-dependent, with individuals in the low-
est quartile of sRAGE exhibiting the highest risk 
for CAD. Importantly, this cohort consisted of a 
non-diabetic population, suggesting that the 
signiﬁ  cance of sRAGE may not be conﬁ  ned to 
diabetes. Falcone et al also showed that the 
association between sRAGE and the risk of CAD 
was independent of other classical risk factors. The 
same research group also showed that patients with 
Alzheimer disease have lower levels of sRAGE in 
plasma than patients with vascular dementia and 
controls, suggesting a role for the RAGE axis in 
this clinical entity as well.
24 Following develop-
ment of an ELISA system to speciﬁ  cally measure 
human esRAGE,
25 we measured plasma esRAGE 
level and cross-sectionally examined its association 
Figure 1. Numerous truncated forms of RAGE. There are three major spliced variants of RAGE: full length, N-terminally truncated, and 
C-terminally truncated. The C-terminally truncated form of RAGE is secreted from the cell and is named endogenously secreted RAGE 
(esRAGE). esRAGE has a V-domain, which is essential for binding with ligands, and is capable of competing with RAGE signaling as a 
decoy receptor. There are other forms of soluble RAGE (sRAGE) that are cleaved from cell-surface RAGE by matrix metalloproteinases. 
The ELISA assay for sRAGE measures all soluble forms including esRAGE in human plasma, while the ELISA for esRAGE measures only 
esRAGE, using polyclonal antibody raised against the unique C-terminus of the esRAGE sequence.333
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with atherosclerosis in 203 type 2 diabetic and 134 
non-diabetic age- and gender-matched subjects.
26 
In this study, type 2 diabetes was diagnosed by 
fasting plasma glucose >126 mg/dl (7 mmol/L), 
causal plasma glucose >200 mg/dl (11.1 mmol/L), 
or 2-hour plasma glucose >200 mg/dl during 75 g 
oral glucose tolerance test, or previous treatment 
for diabetes. esRAGE levels were inversely cor-
related with carotid and femoral atherosclerosis, 
as measured as intimal-medial thickness (IMT) by 
arterial ultrasound (Fig. 2). Stepwise regression 
analyses revealed that plasma esRAGE was the 
third strongest and an independent factor associ-
ated with carotid IMT, following age and systolic 
blood pressure. Another Japanese research group 
also found an inverse correlation between plasma 
esRAGE and carotid atherosclerosis in type 1
27 
and type 2 diabetic subjects.
28 Thus, plasma 
esRAGE or sRAGE may protect against the occur-
rence of cardiovascular diseases, though this 
hypothesis needs to be tested in a longitudinal 
cohort study.
Several metabolic components well-established 
as risk factors for cardiovascular diseases have also 
been shown to be associated with altered plasma 
sRAGE or esRAGE levels. We have shown that 
plasma esRAGE levels are decreased in subjects 
with metabolic syndrome and are inversely cor-
related with several components of metabolic 
syndrome including body mass index, blood pres-
sures, insulin resistance index, fasting plasma 
glucose, serum triglyceride, and lower HDL-cho-
lesterol levels.
26 The majorities of these correla-
tions remained significant even when the 
non-diabetic or type 2 diabetic subpopulation was 
extracted for analyses, again suggesting that 
plasma esRAGE plays important roles even in the 
non-diabetic population. An inverse correaltion 
between esRAGE (or sRAGE) and body mass 
index was also found for control subjects,
29 those 
with type 1 diabetes,
30 and those with end-stage 
renal disease (ESRD).
31 Moreover, patients with 
hypertension have been found to have lower 
plasma sRAGE or esRAGE levels.
26,32
The findings regarding plasma levels of the 
soluble form of RAGE in diabetes are quite 
confusing. We and other groups have found that 
plasma esRAGE level is significantly lower in 
type 1 and type 2 diabetic patients than in non-
Table. Levels of Circulating soluble RAGE in cardio-
vascular and metabolic diseases.
sRAGE   references
CAD (non-DM)  decreased  23
 increased  35
Diabetes (type 1)  increased  33
Diabetes (type 2)  increased  34,35
 decreased  36
Hypertension decreased  32
Alzheimer’s disease  decreased  24
  
esRAGE  
Metabolic syndrome  decreased  26
Diabetes (type 1)  decreased  25,27
Diabetes (type 2)  decreased  26 
Hypertension decreased  26
Atherosclerosis (IMT)  inverse relation  26–28
Figure 2. Plasma esRAGE level is inversely correated with carotid and femoral atherosclerosis. Atherosclerosis was determined as intimal-





26,27 However, plasma sRAGE 
levels have been shown to be increased in type 
1
33 and type 2 diabetic patients,
34,35 although 
conflicting findings have been reported.
36 Of 
note, when diabetic subjects alone were 
extracted for analyses, a direct association was 
not observed between plasma soluble RAGE 
(both sRAGE and esRAGE) levels and the sta-
tus of glycemic control (ie, glycohemoglobin 
A1c).
26,30,36–38 Thus, these complex findings in 
diabetic subjects suggest that levels of plasma 
soluble forms of RAGE are not determined 
simply by status of glycemic control, and that 
even plasma esRAGE and sRAGE levels may 
be under the control of distinct mechanisms.
Plasma esRAGE Levels in Chronic 
Kidney Diseases
Abnormal chronic inﬂ  ammation associated with 
progressive, chronic kidney disease (CKD) 
reﬂ  ects sustained activation of inﬂ  ammatory cells, 
such as monocytes/macrophages, in which accu-
mulation of AGEs may play an important role 
through binding with RAGE. It has been shown 
that, in peripheral monocytes from subjects with 
varying severities of CKD, RAGE expression is 
closely associated with worsening of CKD and is 
strongly correlated with plasma levels of pento-
sidine, a marker for AGEs.
39 In ESRD subjects 
with high-grade inﬂ  ammation, stimulation of 
mononuclear cells with AGE-modiﬁ  ed human 
serum albumin causes a rapid, dose-dependent 
increase in NF-κB activity that could be com-
pletely blocked by an anti-RAGE antibody.
40 
Thus, enhanced RAGE expression in ESRD may 
amplify AGEs-induced perturbation and contrib-
ute to systemic inﬂ  ammatory diseases like ath-
erosclerosis. Circulating esRAGE and sRAGE 
levels have been shown to be increased in patients 
with decreased renal function, particularly those 
with ESRD.
34,38,41 As shown in Figure 3, plasma 
esRAGE levels are positively correlated with 
urinary excretion rate, and inversely correlated 
with estimated glomerular ﬁ  tration rate in type 2 
diabetic patients. It remains to be determined 
whether this increase is caused by decreased renal 
function alone or whether esRAGE levels are 
upregulated to protect against toxic effects of the 
RAGE ligands. Successful kidney transplantation 
resulted in significant decrease in plasma 
sRAGE,
42 implying that the kidneys play a role 
in sRAGE removal.
Low circulating esRAGE Level 
predicts Cardiovascular Diseases: 
A Longitudinal Study
We recently reported an observational cohort study 
in patients with ESRD and for the ﬁ  rst time longi-
tudinally evaluated the effect of plasma esRAGE 
on cardiovascular mortality.
31 Patients with ESRD 
have been reported to have a substantially increased 
rate of cardiovascular mortality. The cohort in that 
study included 206 ESRD subjects registered 
between June 1992 and June 1995, who had been 
treated by regular hemodialysis for more than 3 
months. At baseline, plasma esRAGE levels in 
ESRD patients were higher than those in subjects 
without renal disease. Similar to subjects without 
renal disease, diabetic ESRD subjects exhibited 
signiﬁ  cantly lower plasma esRAGE levels than 
non-diabetic ESRD subjects. Plasma esRAGE 
levels were inversely correlated with many of the 
components of metabolic syndrome, such as 
increase in body mass index, increase in fasting 
plasma glucose, increased triglyceride level and 
decreased HDL cholesterol, even in ESRD sub-
jects. The subjects were followed up until Decem-
ber 2001, with a median follow-up period of 111 
months. At the end of follow-up, 132 patients were 
conﬁ  rmed to be alive on hemodialysis and 74 to 
have died. The 74 deaths during follow-up included 
34 due to fatal cardiovascular events.
Even though the plasma esRAGE levels at 
baseline were higher in ESRD subjects than in 
those without kidney disease, the subjects in the 
lowest tertile of plasma esRAGE levels exhibited 
signiﬁ  cantly higher cardiovascular mortality, but 
not non-cardiovascular mortality (Fig. 4). Uni-
variate Cox proportional hazards analyses revealed 
that, compared with the subjects in the lowest 
tertile of plasma esRAGE levels, those in the 
middle and highest tertiles had signiﬁ  cantly less 
risk of cardiovascular mortality (hazard ratios 0.26 
and 0.40, respectively). Multivariate Cox propor-
tional hazards analyses revealed that the higher 
risk of the subjects with lower esRAGE levels was 
not significant when adjusted for age, fasting 
plasma glucose or presence of diabetes, suggesting 
that esRAGE, aging, and glycemic control mutu-
ally interact in the regulation of cardiovascular 
mortality. Adjustment for other confounders of 335
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esRAGE (body mass index, triglyceride, and HDL 
cholesterol) barely affected the signiﬁ  cant asso-
ciation between lower esRAGE level and cardio-
vascular mortality. Moreover, the association of 
lower esRAGE level with cardiovascular mortality 
was independent of other predictors of cardiovas-
cular mortality such as serum creatinine, non-HDL 
cholesterol, HbA1c, and vascular complications. 
Our ﬁ  ndings thus suggest that low circulating 
esRAGE level is a predictor for atherosclerosis and 
cardiovascular events in patients with ESRD. Since 
this study was designed to survey predictors for 
cardiovascular mortality in the population of ESRD 
patients, and the number of fatal events was rela-
tively small and statistical power may not have 
been high enough to detect important cardiovas-
cular risk factors, demonstration of the role of 
plasma esRAGE as a biomarker of cardiovascular 
mortality will require further large-scale prospec-
tive studies or nested case-control studies with 
required numbers of subjects calculated by power 
analysis.
It is not known at present how esRAGE is 
involved in cardiovascular mortality. In our ESRD 
cohort, neither plasma pentosidine nor carboxy-
methyl-lysine level predicted cardiovascular mor-
tality. Moreover, the inverse correlation between 
low circulating esRAGE level and cardiovascular 
mortality was not dependent of plasma AGEs lev-
els. Thus, the protective effect of esRAGE against 
cardiovascular mortality may not be entirely depen-
dent on neutralization of toxic AGEs. Other endog-
Figure 4. Low plasma esRAGE level is a predictor of cardiovascular mortality in patients with ESRD. Cumulative mortalities in subjects with 
the lowest, middle, and highest tertiles of plasma esRAGE levels were estimated by Kaplan Meier analysis and the log-rank test. Reproduced 
from a reference.
31
Figure 3. Plasma esRAGE level is inﬂ  uenced by the presence of kidney disease in patients with type 2 diabetes. UAE: urinary albumin 
excretion, GFR: glomerular ﬁ  ltration rate estimated by MDRD equation.336
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enous ligands for RAGE, such as S100A12, may 
also be involved in the function of esRAGE. The 
plasma level of S100A12 has been shown to be 
increased in diabetes and inversely correlated with 
serum sRAGE level.
36,43
sRAGE vs. esRAGE: Distinct 
Pathophysiological Signiﬁ  cances?
It is unclear at present whether the pathophysio-
logical signiﬁ  cances of circulating esRAGE and 
sRAGE are distinct in different clinical settings. It 
appears that esRAGE represents less than half of 
the total sRAGE in human plasma. In our analyses, 
plasma esRAGE level in Japanese healthy subjects 
was found to be 0.25 ± 0.11 ng/ml,
26 while mean 
plasma sRAGE level in Caucasian healthy controls 
has been reported to be 1.3 ng/ml.
23 We and others 
have shown that plasma esRAGE level is decreased 
in diabetes.
26,27 In contrast to the case of esRAGE, 
circulating sRAGE levels are increased, rather than 
decreased, in both type 1 and type 2 diabetic 
patients,
33–35 with one conﬂ  icting report.
36 Hump-
ert et al also showed that sRAGE but not esRAGE 
is associated with albuminuria in patients with type 
2 diabetes.
38 Yamamoto et al
44 recently described 
a head-to-head comparison of plasma esRAGE and 
sRAGE levels using esRAGE as a standard protein 
and different sets of antibodies, and showed that 
plasma esRAGE level was about 2-fold less than 
that of plasma sRAGE. In their analysis, esRAGE 
and sRAGE levels were positively correlated, with 
a stronger correlation in healthy subjects than in 
type 1 diabetic patients. Thus, the possibility of 
distinct roles for them in certain disease conditions 
requires further examination.
Soluble RAGE as a Therapeutic 
Target?
The potential usefulness of soluble RAGE for 
prevention and treatment of inﬂ  ammatory diseases 
has been demonstrated in many animal models. Block-
ade of RAGE by administration of genetically engi-
neered sRAGE successfully prevented the development 
of micro-
8,9 and macrovascular complications in dia-
betes.
45–47 We have also shown that adenoviral over-
expression of esRAGE successfully restored the 
impaired angiogenic response in diabetic mice.
20 
Sakaguchi et al found that administration of sRAGE 
markedly suppressed neointimal formation following 
arterial injury in non-diabetic mice.
48 Soluble RAGE 
has also been shown to effectively prevent the devel-
opment of diabetes,
49 protect against tumor growth 
and metastasis,
50 improve the outcome of colitis,
51 
restore impaired wound healing,
52 and suppress 
Alzheimer disease-like conditions.
53 These effects of 
soluble RAGE in animal models could be explained 
by its decoy function, inhibiting RAGE interaction 
with its proinﬂ  ammatory ligands, which might be 
applicable to human diseases as well.
Further application of soluble RAGE to the treat-
ment of human diseases will require answers to 
several questions. Most importantly, limited ﬁ  ndings 
are available regarding the mechanisms of regula-
tion of circulating esRAGE or sRAGE in humans. 
A tissue microarray technique using a wide variety 
of adult normal human preparations obtained from 
surgical and autopsy specimens revealed that 
esRAGE was widely distributed in tissues, including 
vascular endothelium, monocyte/macrophage, pneu-
mocytes, and several endocrine organs.
54 However, 
it is unclear at present from which organ or tissue 
plasma sRAGE or esRAGE originate. Circulating 
AGEs may be involved in regulation of the secretion 
or production of soluble RAGE, since AGEs are 
known to upregulate RAGE expression in vitro.
55 
esRAGE could be simultaneously upregulated by 
AGEs and act as a negative feedback loop to com-
pensate for the damaging effects of AGEs. Several 
studies have found positive correlations between 
plasma sRAGE or esRAGE and AGEs. 
29–31,34 This 
possibility is further supported by the ﬁ  ndings that 
the suppression of sRAGE expression in diabetic 
rat kidney is reversed by blockade of AGEs accu-
mulation with alagebrium.
56 Other inﬂ  ammatory 
mediators, such as S100, tumor necrosis factor α, 
and C-reactive protein, could also be potential can-
didates for regulation of the plasma level of soluble 
RAGE in humans.
36,55,57 Without doubt, further 
understanding of the regulation of soluble RAGE 
will be most helpful in delineating potential targets 
for therapeutic application of soluble RAGE.
Second, it would be important to determine 
whether currently available pharmacological 
agents can regulate plasma sRAGE or esRAGE. 
Forbes et al
58 showed that inhibition of angioten-
sin-converting enzyme (ACE) in rats increased 
renal expression of sRAGE, and that this was 
associated with decreases in expression of renal 
full-length RAGE protein. They also showed that 
plasma sRAGE levels were signiﬁ  cantly increased 
by inhibition of ACE in both diabetic rats and in 337
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human subjects with type 1 diabetes. Thus, one 
attractive scenario is that the protective effect of 
ACE inhibition against progression of renal dys-
function is mediated through regulation of RAGE 
versus soluble RAGE production. Other potential 




both of which are known to modulate the AGEs-
RAGE system in culture, although their effects on 
secretion of soluble RAGE are not known.
Taken altogether, the ﬁ  ndings discussed here 
suggest that sRAGE or esRAGE could serve as a 
novel biomarker for estimation of the risk of pro-
gression of atherosclerotic disorders. Further 
examination of the molecular mechanisms underly-
ing RAGE and esRAGE regulation will provide 
important insights into potential targets for the pre-
vention and treatment of cardiovascular diseases.
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